Pfizer Inc. (PFE) Stake Decreased by Windsor Financial Group LLC
Windsor Financial Group LLC cut its stake in Pfizer Inc. (NYSE:PFE) by 3.5% during the third quarter, according to its most recent disclosure with the SEC. The fund owned 127,323 shares of the biopharmaceutical company’s stock after selling 4,642 shares during the period. Pfizer accounts for 2.0% of Windsor Financial Group LLC’s portfolio, making the stock its 23rd largest position. Windsor Financial Group LLC’s holdings in Pfizer were worth $4,312,000 as of its most recent filing with the SEC.
Other hedge funds have also modified their holdings of the company. First Hawaiian Bank boosted its stake in Pfizer by 0.3% in the third quarter. First Hawaiian Bank now owns 8,585 shares of the biopharmaceutical company’s stock worth $291,000 after buying an additional 24 shares during the last quarter. Ronna Sue Cohen boosted its stake in shares of Pfizer by 0.4% in the second quarter. Ronna Sue Cohen now owns 7,881 shares of the biopharmaceutical company’s stock worth $277,000 after buying an additional 35 shares in the last quarter. Alpha Windward LLC boosted its stake in shares of Pfizer by 0.5% in the third quarter. Alpha Windward LLC now owns 8,315 shares of the biopharmaceutical company’s stock worth $282,000 after buying an additional 40 shares in the last quarter. Delphi Private Advisors LLC boosted its stake in shares of Pfizer by 1.2% in the second quarter. Delphi Private Advisors LLC now owns 4,007 shares of the biopharmaceutical company’s stock worth $141,000 after buying an additional 47 shares in the last quarter. Finally, Acadia Trust NA boosted its stake in shares of Pfizer by 0.5% in the second quarter. Acadia Trust NA now owns 14,032 shares of the biopharmaceutical company’s stock worth $494,000 after buying an additional 67 shares in the last quarter. 68.53% of the stock is owned by institutional investors and hedge funds.
Pfizer Inc. (NYSE:PFE) traded up 0.69% on Wednesday, reaching $32.14. The company’s stock had a trading volume of 38,503,153 shares. Pfizer Inc. has a 12 month low of $28.25 and a 12 month high of $37.39. The firm has a market cap of $195.04 billion, a P/E ratio of 32.27 and a beta of 0.90. The firm’s 50 day moving average is $31.95 and its 200-day moving average is $34.15.
Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, November 1st. The biopharmaceutical company reported $0.61 EPS for the quarter, missing the consensus estimate of $0.62 by $0.01. The business had revenue of $13.05 billion for the quarter, compared to the consensus estimate of $13.05 billion. Pfizer had a return on equity of 23.68% and a net margin of 13.09%. The company’s revenue was up 7.9% on a year-over-year basis. During the same period in the previous year, the firm earned $0.60 earnings per share. On average, equities research analysts anticipate that Pfizer Inc. will post $2.41 EPS for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Thursday, December 1st. Stockholders of record on Friday, November 11th will be given a dividend of $0.30 per share. This represents a $1.20 annualized dividend and a dividend yield of 3.73%. The ex-dividend date is Tuesday, November 8th. Pfizer’s payout ratio is presently 106.20%.
TRADEMARK VIOLATION NOTICE: “Pfizer Inc. (PFE) Stake Decreased by Windsor Financial Group LLC” was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this article on another site, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The legal version of this article can be viewed at https://www.thecerbatgem.com/2016/11/30/pfizer-inc-pfe-stake-decreased-by-windsor-financial-group-llc.html.
A number of analysts have weighed in on the company. Vetr raised Pfizer from a “buy” rating to a “strong-buy” rating and set a $37.42 price target for the company in a research report on Monday, October 17th. Sanford C. Bernstein reaffirmed an “outperform” rating on shares of Pfizer in a research report on Monday, September 26th. Barclays PLC raised Pfizer from an “equal weight” rating to an “overweight” rating and set a $38.00 price target for the company in a research report on Tuesday. Argus cut Pfizer from a “buy” rating to a “hold” rating in a research report on Wednesday, November 2nd. Finally, Bank of America Corp. reaffirmed a “buy” rating and issued a $36.00 price target (down previously from $40.00) on shares of Pfizer in a research report on Monday, November 7th. Twelve investment analysts have rated the stock with a hold rating, eleven have given a buy rating and two have given a strong buy rating to the company. Pfizer has a consensus rating of “Buy” and an average target price of $37.91.
In other news, insider Anthony J. Maddaluna sold 10,000 shares of the business’s stock in a transaction dated Wednesday, November 9th. The shares were sold at an average price of $33.00, for a total transaction of $330,000.00. Following the completion of the sale, the insider now directly owns 112,087 shares of the company’s stock, valued at $3,698,871. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Albert Bourla sold 18,390 shares of the business’s stock in a transaction dated Friday, November 4th. The stock was sold at an average price of $30.05, for a total transaction of $552,619.50. Following the sale, the insider now directly owns 149,199 shares of the company’s stock, valued at $4,483,429.95. The disclosure for this sale can be found here. Insiders own 0.07% of the company’s stock.
Pfizer Inc is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its portfolio includes medicines, vaccines and medical devices, as well as consumer healthcare products. Its products include Prevnar/Prevenar 13, Lyrica, Enbrel, Lipitor, Viagra, Sutent, BeneFIX, Genotropin, ReFacto, Xyntha and Enbrel.
Receive News & Stock Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related stocks with our FREE daily email newsletter.